Mode
Text Size
Log in / Sign up
N/A Completed N=12 Treatment

Buprenorphine/Raltegravir Pharmacokinetic Interaction Study

Source: ClinicalTrials.gov NCT00858962 ↗
Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Nov 2012
Primary outcomePrimary: Area Under the Curve (AUC) of BUP/NLX With Raltegravir (hr*ng/mL) — 56.0 hr*ng/mL

Summary

The main purpose of this protocol is to study the effect of an HIV medication known as Raltegravir on Buprenorphine in people who have been receiving the same dose of Buprenorphine for at least 3 weeks before study entry. This will be determined by giving Raltegravir along with Buprenorphine and by measuring the amount of Raltegravir and Buprenorphine in the blood. The investigators will also learn about the effects of Buprenorphine on Raltegravir and about the safety of taking these two medications together.

Outcome Measures

OutcomeResultp-value
PRIMARY
Area Under the Curve (AUC) of BUP/NLX With Raltegravir (hr*ng/mL)
56.0 —

Eligibility Criteria

Inclusion Criteria

  • Patients who are opioid dependent on long-term buprenorphine/naloxone (BUP/NLX) maintenance (minimum of 4 weeks) and who must remain at a stable dose of buprenorphine for at least 3 weeks deemed by the investigator to have acceptable medical history, physical examination and clinical laboratory evaluations consistent with BUP maintenance will be eligible to participate in the study.
  • Body weight >60 kg for males and >40 kg for females
  • Male or females, ages > 21 to 3.0X the upper limit of normal
  • Hemoglobin < 9 g/dL, and platelet count < 75,000/mm3.
  • Positive serum or urine for HCG.
  • History of any significant drug allergy, drug rash or sensitivity to any class of drugs relevant to the study drugs.
  • HIV antibody positive
  • Exposure to any investigational drug within 4 weeks of enrollment and throughout the study.
  • Prior exposure to Raltegravir.
  • Use of any agent (prescribed or otherwise) within 2 weeks of dosing, that is known or suspected to induce or inhibit drug metabolizing enzymes (e.g., cimetidine and compounds in the barbiturate and phenothiazine classes), affect renal tubular secretion (e.g., probenecid, beta-lactam antibiotics), gastrointestinal motility (e.g., metoclopramide, propantheline, loperamide, or narcotic analgesics or opioids other than buprenorphine/naloxone), or uric acid metabolism (e.g., allopurinol) or gastrointestinal pH (including antacids, H2-receptor antagonists, proton pump inhibitors etc.).
  • Use of over-the-counter medications and herbal preparations, within 1 week prior to enrollment and throughout the study.
  • Use of St. John's Wort (Hypericum) within four weeks prior to study enrollment and throughout the study.
  • Consumption of grapefruit or grapefruit juice within 1 week of study entry and throughout the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00858962). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search